Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.

• Status: Unknown status
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to determine the anti-anginal and anti-ischemic effect of k-channel opener, nicorandil in patients of chronic stable angina.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferozsons Laboratories Ltd.
• Treatments: Atenolol; Nicorandil

Criteria

Inclusion Criteria:

1. Patients of chronic stable angina with abnormal Exercise Myocardial Perfusion Spect Scan with reversible and partially reversible ischemic changes.

2. Male and female

3. Age 25 to 65 years

4. Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the diary cards.

5. Patient must be able to give voluntary written informed consent.

Exclusion Criteria:

1. Hypertension of > 170/100 mm of Hg

2. Valvular heart disease and cardiomyopathy

3. Myocardial infarction in < 6 months

4. Unstable angina

5. Congestive cardiac failure

6. Severe anemia (Hb 7G/dl)

7. Cardiac arrhythmias or II or III degree AV block

8. Significant liver or renal dysfunction

9. IDDM (Type-1 diabetes mellitus)

10. Systolic blood pressure < 100 mm Hg

11. Pregnant and nursing women

12. Known hypersensitivity to nicorandil

13. On calcium channel blockers

14. Patients not eligible for Tc 99m SPECT

15. Patients in whom beta blockers are contraindicated

16. Geographical inaccessibility for treatment or follow-up evaluations